Skip to content

Study · Randomized controlled trial · n = 144 · 2018

6 results

Mid-luteal phase gonadotropin-releasing hormone agonist support in frozen-thawed embryo transfers during artificial cycles: A prospective interventional pilot study.

Seikkula J, Ahinko K, Polo-Kantola P, Anttila L, Hurme S, Tinkanen H, Jokimaa V

Journal of gynecology obstetrics and human reproduction20 Apr 2018Cited by 16 (Europe PMC)

PMID29684629 (opens in a new tab)DOI10.1016/j.jogoh.2018.04.009 (opens in a new tab)PepBankPUB-29684629
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In frozen embryo transfer cycles, additional triptorelin did not significantly increase live birth rates versus standard HRT.

    In plain wordsIn frozen embryo transfer cycles, additional triptorelin did not significantly increase live birth rates versus standard HRT.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLive birth rate
    Study

    n = 144

    Comparator
    Standard HRT
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Measurements

    Live birth rate difference
    9.8 percentage points
    triptorelin versus control

    Source sentences

    Summary
    The live birth rate (LBR) was 9.8 percentage points higher and the miscarriage rate 14.7 percentage points lower in the intervention group (n=72) than in the control group (n=72), but the differences did not reach statistical significance.
    2 context sentences
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.
    Summary · context
    Altogether, 144 FET cycles were analyzed.
  2. 02HumanRandomized controlled trialSafety outcome

    In frozen embryo transfer cycles, additional triptorelin did not significantly reduce miscarriage rates versus standard HRT.

    In plain wordsIn frozen embryo transfer cycles, additional triptorelin did not significantly reduce miscarriage rates versus standard HRT.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeMiscarriage rate
    Study

    n = 144

    Comparator
    Standard HRT
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Measurements

    Miscarriage rate reduction
    14.7 percentage points
    triptorelin versus control

    Source sentences

    Summary
    The live birth rate (LBR) was 9.8 percentage points higher and the miscarriage rate 14.7 percentage points lower in the intervention group (n=72) than in the control group (n=72), but the differences did not reach statistical significance.
    2 context sentences
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.
    Summary · context
    Altogether, 144 FET cycles were analyzed.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In frozen embryo transfer cycles, implantation rates were comparable with additional triptorelin and standard HRT.

    In plain wordsIn frozen embryo transfer cycles, implantation rates were similar with additional triptorelin and standard HRT.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeImplantation rate
    Study

    n = 144

    Comparator
    Standard HRT
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Implantation and clinical pregnancy rates were comparable between the groups.
    2 context sentences
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.
    Summary · context
    Altogether, 144 FET cycles were analyzed.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In frozen embryo transfer cycles, clinical pregnancy rates were comparable with additional triptorelin and standard HRT.

    In plain wordsIn frozen embryo transfer cycles, clinical pregnancy rates were similar with additional triptorelin and standard HRT.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n = 144

    Comparator
    Standard HRT
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Implantation and clinical pregnancy rates were comparable between the groups.
    2 context sentences
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.
    Summary · context
    Altogether, 144 FET cycles were analyzed.
  5. 05HumanRandomized controlled trialSafety outcome

    After frozen embryo transfer with additional triptorelin or standard HRT, no congenital malformations were detected.

    In plain wordsAfter frozen embryo transfer with additional triptorelin or standard HRT, no congenital malformations were detected.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableCongenital malformations
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No congenital malformations or differences in the median birth weight of newborns were detected.
    1 context sentence
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.
  6. 06HumanRandomized controlled trialSafety outcome

    After frozen embryo transfer, median newborn birth weight did not differ between additional triptorelin and standard HRT groups.

    In plain wordsAfter frozen embryo transfer, median newborn birth weight was similar with additional triptorelin and standard HRT.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeMedian newborn birth weight
    Study

    n: not reported in source

    Comparator
    Standard HRT
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.1 mg, single dose · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No congenital malformations or differences in the median birth weight of newborns were detected.
    1 context sentence
    Summary · context
    Women scheduled for FET were randomly selected to receive standard hormonal replacement therapy (HRT) for endometrial preparation or HRT with a single additional subcutaneous dose of 0.1mg triptorelin at the time of implantation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.